期刊
CLINICAL SCIENCE
卷 131, 期 14, 页码 1723-1735出版社
PORTLAND PRESS LTD
DOI: 10.1042/CS20160253
关键词
-
资金
- AZ/Medimmune
- GSK
- Chiesi
- Novartis
- Regeneron
- Sanofi
- Gilead
- Glenmark
- TEVA
- BI
- Roche/Genentech
- Pfizer
The pathogenesis of asthma is complex and multi-faceted. Asthma patients have a diverse range of underlying dominant disease processes and pathways despite apparent similarities in clinical expression. Here, we present the current understanding of asthma pathogenesis. We discuss airway inflammation (both T2(HIGH) and T2(LOW)), airway hyperresponsiveness (AHR) and airways remodelling as four key factors in asthma pathogenesis, and also outline other contributory factors such as genetics and co-morbidities. Response to current asthma therapies also varies greatly, which is probably related to the inter-patient differences in pathogenesis. Here, we also summarize how our developing understanding of detailed pathological processes potentially translates into the targeted treatment options we require for optimal asthma management in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据